:: Volume 6, Issue 3 (Int Biol Biomed J (In press) 2020) ::
IBBJ 2020, 6(3): 0-0 Back to browse issues page
Insights in the management of human T cell-lymphotropic virus-1 associated adult-T cell leukaemia/lymphoma (ATL).
Angel Justiz Vaillant *
University of the West Indies. St. Augustine , angel.vaillant@sta.uwi.edu
Abstract:   (3049 Views)
The present paper refers to some of the most critical aspects of the management of adult-T cell leukaemia/lymphoma (ATL), which is a rare malignancy that affect the 5-7% of infected with human T cell-lymphotropic virus-1 (HTLV-1). ATL has a geographical distribution that includes countries such as Japan, the Caribbean, Central and South America and sub-Saharan Africa. The ATL management includes the use of antivirals, monoclonal antibodies, chemotherapy, radiotherapy, hematopoietic stem cell transplantation (HSCT) and more modern experimental approach, which are promising as immunotherapy. Despite available therapy the prognosis  of ATL remains poor, but it may improve in the upcoming years with the parallel advancement in the basic medical sciences.
Keywords: Adult-T cell leukaemia/lymphoma, Management, Cancer, Hematopoietic stem cell transplantation (HSCT), Immunotherapy
     
Type of Study: Mini Review | Subject: Clinical Medicine
Received: 2020/03/29 | Accepted: 2021/02/17 | Published: 2021/02/17


XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 6, Issue 3 (Int Biol Biomed J (In press) 2020) Back to browse issues page